Apyx Medical Corporation (APYX) Stock: Price, Forecast & Analyst Target
Apyx Medical Corporation (APYX) — MoonshotScore 33/100 (Weak band), calculated Nov 18, 2026. Price $2.39 (-4.02%), as of the Nov 19, 2026 trading session; market cap $101M.
Educational signal · not a buy or sell recommendation · How to read this
Apyx Medical Corporation · APYX · NASDAQ
Apyx Medical Corporation is an energy technology company focused on developing and marketing medical devices for the cosmetic and surgical markets. Their key product, Renuvion, utilizes helium plasma technology for tissue coagulation and ablation.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Apyx Medical (APYX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fragile balance sheet and a full valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Average; Financial Safety: Strained; Valuation: Full; Growth Durability: Growing; Momentum: Quiet.
- EPS beat 0 of the last 4 reports
- Altman Z 0.75 · Piotroski F 3
Holding back: balance-sheet strain
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $2.39 | |
| Change on the day | -4.02% | |
| Market capitalisation | $101M | — |
| Shares traded on the day | 107.2K |
Price & events
Other perspectives
Council score for Apyx Medical (APYX): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Apyx Medical (APYX), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Apyx Medical Corporation (APYX) is listed on NASDAQ. It employs 205 people. The market values it at $101M.
What do the latest results show for Apyx Medical (APYX)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $13M | -$2M | -$0.05 (diluted) |
| Q4 FY2025 | $19M | -$1M | -$0.03 (diluted) |
| Q1 FY2026 | $12M | -$2M | -$0.05 (diluted) |
| Q2 FY2026 | $14M | -$3M | -$0.07 (diluted) |
What are the financial strengths and risks for Apyx Medical (APYX)?
Short answer
What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z 0.75 · Piotroski F 3. Trailing ratios: ROA -3.4% · current ratio 4.95.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.75 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Apyx Medical (APYX)?
Short answer · as of
Current published price targets run low $6.00 · high $7.00 · consensus $6.50 · median $6.50 against a quoted price of $2.39 (as of Nov 19, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Apyx Medical compare with its peers?
Short answer
Apyx Medical's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $92.07 Nov 19, 2026 | $5.07B | 88 5-pillar Nov 18, 2026 | |
| $8.52 Nov 20, 2026 | $323M | 88 5-pillar Nov 18, 2026 | |
| $8.73 Nov 19, 2026 | $351M | 87 5-pillar Nov 18, 2026 | |
| $22.98 Nov 20, 2026 | $188M | 87 5-pillar Nov 18, 2026 | |
| $13.23 Nov 20, 2026 | $177M | 71 5-pillar Nov 18, 2026 | |
| $4.64 Nov 19, 2026 | $57.1M | 44 5-pillar Nov 18, 2026 | |
| $1.49 Nov 20, 2026 | $93.7M | 43 5-pillar Nov 18, 2026 | |
| $3.23 Nov 19, 2026 | $96.5M | 41 5-pillar Nov 18, 2026 | |
| $2.08 Nov 20, 2026 | $31.7M | 39 5-pillar Nov 18, 2026 | |
| $5.30 Nov 20, 2026 | $138M | 37 5-pillar Nov 18, 2026 | |
| $6.07 Nov 20, 2026 | $247M | 36 5-pillar Nov 18, 2026 | |
| $8.67 Nov 20, 2026 | $361M | 35 5-pillar Nov 18, 2026 | |
| Apyx Medical (APYX) — this page | $2.39 | $101M | 33 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $6.00 – $7.00
- Consensus target
- $6.50
- Median target
- $6.50
Consensus record · Captured .
Measured against a quoted price of $2.39 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jun 30, 2026
- Transactions
- 14
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 0
- Other transactions
- 14
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held APYX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported APYX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Apyx Medical (APYX)?
Investor Questions: APYX Stock
These answers are editorial: 1 of these 9 answers is drawn from the APYX research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for APYX?
APYX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is APYX a good stock to buy?
Stock Expert AI does not rate APYX buy, sell or hold. Apyx Medical Corporation carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the APYX stock price today?
The last price recorded for Apyx Medical Corporation (APYX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the APYX price target?
The analyst consensus price target for Apyx Medical Corporation (APYX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What revenue streams does Apyx Medical Corporation have in healthcare?
Apyx Medical Corporation generates revenue primarily through the sale of its Renuvion and J-Plasma products, as well as related disposable hand pieces and accessories. The company's revenue streams can be broken down by product line, therapeutic area, and geographic market.
What are the key factors to evaluate for APYX?
Apyx Medical Corporation (APYX) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Apyx Medical's J-Plasma product is used in the hospital surgical market. Not financial advice.
How frequently does APYX data refresh on this page?
APYX's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven APYX's recent stock price performance?
Apyx Medical Corporation (APYX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Renuvion technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider APYX overvalued or undervalued right now?
Apyx Medical Corporation (APYX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 11 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com